|
Valacyclovir Clinical Trials
4 actively recruiting trials across 3 locations
▲ +1 trial since August 2026
Also known as: ValACV, Valaciclovir, Valtrex, Zelitrex
Pipeline
Phase 1: 1Phase 2: 2Phase 3: 1
Top Sponsors
- University of Michigan Rogel Cancer Center1
- The Methodist Hospital Research Institute1
- M.D. Anderson Cancer Center1
- Candel Therapeutics, Inc.1
Indications
- Cancer4
- Recurrent Diffuse Hemispheric Glioma, H3 G34-Mutant1
- Recurrent Malignant Brain Neoplasm1
- Resectable Brain Neoplasm1
- Non-Squamous Non-Small Cell Lung Cancer1
Houston, Texas2 trials
Phase II High Risk Prostate Cancer Trial Using Gene & Androgen Deprivation Therapies, Radiotherapy, & Surgery
Houston Methodist Hospital
Phase 2
Ann Arbor, Michigan1 trial
Virus-Based Gene Therapy (AdV-HSV1-TK and AdV-Flt3L) in Combination With Valacyclovir for the Treatment of Pediatric and Young Adult Patients With Resectable, Recurrent Primary Malignant Brain Tumors
University of Michigan Comprehensive Cancer Center
Phase 1
New York, New York1 trial
Aglatimagene Besadenovec + Prodrug and Pembrolizumab vs Docetaxel for Stage IV Non-Squamous NSCLC Progressing on Pembrolizumab (AURORA)
Laura & Isaac Perlmutter Cancer Center at NYU Langone Health
Phase 3
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.